Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines (LAIVs) against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development ...
Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, ...
Tags: Soligenix, NIAID, ThermoVax, Drs.John Carpenter
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option to conduct the investigational new drug (IND) enabling program and to submit an IND. ...
Tags: BioCryst, NIAID, investigational new drug, BCX4430, Marburg virus disease
Pfenex has received a subcontract from Leidos Holdings (LDOS) to support the development of an anthrax vaccine containing its recombinant protective antigen (rPA) and a novel, immune-enhancing adjuvant. The initial contract was awarded by ...
Tags: Pfenex, Anthrax Vaccine
Signum Dermalogix, a biopharmaceutical company, has announced that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the company a Small Business Innovation Research (SBIR) Phase II grant totaling ...
U.S. researchers began an early stage clinical trial of a vaccine to prevent genital herpes disease by removing two key proteins so the virus cannot multiply. Principal investigator Dr. Lesia K. Dropulic of the National Institute of ...
Tags: vaccine, genital herpes, protein, virus
Transgene has received a sub-award from Emergent BioSolutions (EBS) under its existing grant of $5m from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), to advance ...
Tags: Transgene, NIH Funding
Biopharmaceutical company Soligenix has secured a contract worth $6.4m from the US Department of Health and Human Service's National Institutes of Health (NIH), for the advanced preclinical development of OrbeShield (oral beclomethasone ...
Corgenix Medical has received the notification of CE Mark for its Relasv antigen rapid test for Lassa fever diagnosis. Relasv is the diagnostic test developed by Corgenix and members of the Viral Hemorrhagic Fever Consortium (VHFC), a ...
Tags: Corgenix Medical, Rapid Test
VaxInnate, a US-based biotechnology firm, has received a grant from the National Institute of Allergy and Infectious Diseases (NIAID) to fund the development of a recombinant vaccine for the prevention of dengue. The grant will provide ...
Researchers at the National Institutes of Health (NIH) have begun enrolling volunteers for clinical trials to find effective treatments for influenza. One of the studies will assess if treatment with the influenza drug oseltamivir reduces ...
The US FDA has granted Soligenix fast track designation for OrbeShield for the reduction of mortality associated with gastrointestinal acute radiation syndrome (GI ARS). The oral beclomethasone 17,21-dipropionate (oral BDP) earlier ...
Tags: US FDA, Soligenix, fast track designation, OrbeShield
SRI International has received a new grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a topical microbicide gel for drug delivery. The topical microbicide gel, which will be based on a patented ...
Collaborative Drug Discovery (CDD) and SRI International have won a second grant from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, for the joint development of an ...
Tags: Collaborative Drug Discovery, CDD, tuberculosis, TB
InVitria, the non-therapeutic products division of Ventria Bioscience, has received a two year small business innovation research program (SBIR) grant from the National Institutes of Health, National Institute of Allergy and Infectious ...